Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
Humacyte reported Q1 2026 revenue of $495,000, with product sales of Symvess increasing to $493,000 from $147,000 in Q1 2025, representing a 93.4% year-over-year growth. The company appointed James Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer to strengthen its commercial and surgical leadership. Humacyte received a $1.475 million purchase commitment from the Kingdom of Saudi Arabia for a clinical evaluation and outreach program, and the Israeli Ministry of Health accepted the Marketing Authorization Application for Symvess.
Key figures
- Revenue
- 495000
- Revenue Yoy
- 93.4%
- Net loss
- 17619000
- Total assets
- 110557000
- Inventory net
- 9920000
- Product sales
- 493000
- Long term debt
- 35871000
- Contract revenue
- 2000
- Total liabilities
- 98933000
- Cost of goods sold
- 2038000
- Total current assets
- 63597000
- Cash and cash equivalents
- 48539000
- Total current liabilities
- 16187000
- Total stockholders equity
- 11624000
- Other long term liabilities
- 1677000
- Contingent earnout liability
- 6760000
- Common stock warrant liabilities
- 10836000
- Research and development expenses
- 19462000
- General and administrative expenses
- 7930000
- Prepaid expenses and other current assets
- 5138000
- Total liabilities and stockholders equity
- 110557000
- Common stock and additional paid in capital
- 756091000
- Finance lease obligation net of current portion
- 27602000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.